Brief Description
HypO2Regen’s is developing novel, disease-modifying therapeutics for chronic intractable inflammatory diseases, including what would be the first cell-free stem cell treatment that induces true regeneration of tissue damaged by chronic inflammation. The company's first focus on improving the lives of more than 300 million people in the United States and Europe with moderate to severe periodontitis, up to 70% of whom are either undertreated or untreated.
Timeline
- 2024. Company founded
Inventors
Phillip Messersmith, Jing Cheng, Ellen Heber-Katz